HEALEY ALS Platform: Multi-Center, Multi-Regimen clinical trial evaluating investigational products for the treatment of ALS
C
Cynthia Bodkin, MD
Primary Investigator
Overview
ALS is a degenerative disorder of the nerves controlling movement (“motor neurons”). ALS causes muscles to become weak, which leads to paralysis. ALS is a condition that gradually damages the nerve cells in the brain and spinal cord. Currently, there are no treatments to prevent, reverse, or stop the development of ALS. However, there are some treatments that may slow down the progression of the disease. We are doing this research to find out if DNL343 can help with Amyotrophic Lateral Sclerosis (ALS). We also want to find out if DNL343 is safe to take without causing too many side effects.
Description
Who is Eligible
- Ages 18+
- Diagnosis of ALS with onset of symptoms within the last 3 years
- Able to swallow pills and liquids
- No history of cancer within last 3 years
- No diagnosis of diabetes
What is Invovled
- In person at IUH Neuroscience Center
- Daily oral medication with weekly appointments at IUH Neuroscience Center with home appointments available after first few weeks.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Amyotrophic Lateral Sclerosis,ALS
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
01 May 2024.
Study ID: 11493
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
